119results about "Group 3/13 organic compounds without C-metal linkages" patented technology

Embodiments of this disclosure are directed to catalyst systems comprising a metal-ligand complex according to formula (I).

The present application relates to a kind of catalyst composition and its application in catalytic preparation optically active secondary alcohol, the catalyst composition includes chiral ionic bridged aryloxyalkane rare earth complex and additive, the additive is selected from one or more of pyrimidine, N,N-dicyclohexylmethylamine, 4,4'-dipyridyl.The above-mentioned catalyst composition can be used for synergistically catalyzing asymmetric borohydration of chalcone and its derivatives with pinacol borane, and show high catalytic activity and high enantioselectivity, product yield is as high as 99%, ee value can reach 84%, provide a reliable new way for the efficient, high selective synthesis of optically active secondary alcohol.

An additive to lubricant, comprising or consisting of a metal complex with the formular (I): (I) wherein R is either PR1R2 or C-NR1R2 wherein in at least one of R1 or R2 comprises of optionally substituted alkanes with nine or more carbon atoms or R1 and R2 are inter-connected by optionally substituted hydrocarbon chains with at least nine carbon atoms, wherein L can be selected from a group consisting of one bidentate ligand, one monodentate ligand / or two separate monodentate ligands, where coordinating atoms are S, N, P and / or O and M is any lanthanide or a mixture of those, except Pm; a use of such compound and a lubricant mixture comprising such a compound.

The present invention relates to an improved process for the preparation of macrocyclic chelant 2,2′,2″-(10-(2-hydroxypropyl)-1,4,7,10-tetraazacyclododecane-1,4,7-triyl) triacetic acid of formula (1). The present invention further relates to the process for the preparation of metal complexes of macrocyclic chelant 2,2′,2″-(10-(2-hydroxypropyl)-1,4,7,10-tetraazacyclododecane-1,4,7-triyl) triacetic acid of formula (1) with purity greater than 99.0% by HPLC. The present invention also relates to an improved process for the preparation of gadolinium complex of formula (1a) with macrocyclic chelant 2,2′,2″-(10-(2-hydroxypropyl)-1,4,7,10-tetraazacyclododecane-1,4,7-triyl) triacetic acid of formula (1). The present invention further relates to a novel process for the preparation of calcium complex of formula (1b) with macrocyclic chelant 2,2′,2″-(10-(2-hydroxypropyl)-1,4,7,10-tetraazacyclododecane-1,4,7-triyl) triacetic acid of formula (1).

Disclosed herein are compounds that target carbonic anhydrase 9 (CA IX) (such as compounds of structural formula (I) or (II) wherein values for variables are as described herein) and methods for the prevention and / or treatment of certain cancers, including solid tumors, using such compounds. Also disclosed herein are pharmaceutically acceptable salts of such compounds and pharmaceutical compositions comprising such compounds or salts for use in such methods of preventing or treating cancers.

The present invention relates to an organoboron covalent organic framework impregnated with at least one salt selected from alkali metal salts and alkaline earth metal salts, the impregnated organoboron covalent organic framework being substantially free of organic solvents. The present invention also relates to a method for preparing the impregnated organoboron covalent organic framework, a use of the impregnated organoboron covalent organic framework as a solid electrolyte in an all-solid-state battery, and a separator for the all-solid-state battery, an electrode for the all-solid-state battery, and an all-solid-state battery, each comprising the impregnated organoboron covalent organic framework.

Embodiments of this disclosure are directed to catalyst systems comprising a metal-ligand complex according to formula (I):

This invention provides neurotensin receptor ligands, pharmaceutical compositions containing neurotensin receptor ligands, methods for using neurotensin receptor ligands for the treatment of diseases, and methods for producing neurotensin receptor ligands. [Solution] The present invention relates to a compound of the following formula: TIFF2026106435000709.tif54128 The present invention also provides pharmaceutical compositions comprising the compound, methods for using the compound for the treatment of diseases, and methods for preparing the compound.

The invention discloses a high-load transparent rare earth complex organic glass scintillator as well as a preparation method and application thereof. The scintillator comprises a polymer matrix and an ionic rare earth complex dispersed in the polymer matrix, the rare earth complex comprises coordination anions and ionic liquid cations, the coordination anions comprise rare earth ions and organic ligands, and the loading capacity of the rare earth complex in the polymer matrix can reach 80-90 wt%. According to the scintillator, an ionic liquid is introduced to construct an ionic supramolecular structure, effective isolation of a luminescence center is realized by utilizing steric hindrance and a charge shielding effect, concentration quenching is inhibited, and compatibility with a matrix is enhanced, so that the material still keeps transparency of 90% or above under an ultrahigh load. The maximum radiation luminous intensity of the scintillator is 23.9 times that of commercial LYSO, the lower detection limit is as low as 56nGy / s, and the scintillator is suitable for the fields of high-energy particle detection, X-ray imaging and the like.

The application relates to the technical field of complex nanomaterials, in particular to a preparation method of an indium complex nanomaterial, the obtained material and application thereof. The application discloses a preparation method of an indium complex nanomaterial, which comprises the following steps: adding inorganic indium salt and 5-bromoisophthalic acid into N,N-dimethylformamide to obtain a transparent reaction liquid; carrying out a solvothermal reaction on the reaction liquid in a reaction kettle; cooling the reaction kettle after the solvothermal reaction, and separating to obtain a solid crude product; washing the solid crude product, drying, and obtaining the indium complex nanomaterial. The application also discloses the indium complex nanomaterial prepared by the above preparation method and application of the indium complex nanomaterial in adsorption of organic dye wastewater. The indium complex nanomaterial prepared by the application has excellent adsorption performance on Congo red dye in a water environment, and also has certain adsorption performance on rhodamine B and methyl orange, and has relatively high practical application value in treatment of organic dye wastewater containing Congo red dye.

The present invention relates to a FAP-α specific tumor diagnostic imaging agent, in particular, the present invention relates to a compound of formula (I), a FAP-α specific tumor imaging agent formed by coordination of the compound of formula (I) with a radionuclide, and use of said compound in the diagnosis of a disease characterized by overexpression of fibroblast activation protein α (FAP-α) in a subject in need thereof.

This disclosure provides a compound represented by the following general formula (1), a thin-film forming raw material containing the compound, a thin-film formed from the thin-film forming raw material, and a method of producing a thin-film: where R1 and R2 each independently represent an alkyl group having 1 to 8 carbon atoms, and R3 represents a hydrogen atom or an alkyl group having 1 to 5 carbon atoms, provided that R1 and R2 represent different groups.

The disclosed lanthanide precursor compounds include cyclopentadienyl ligands having at least one aliphatic group as a substituent and at least one bidentate ligand. These precursors are suitable for depositing lanthanide-containing films.

The present disclosure relates to pharmaceutical formulations of contrast agents used in magnetic resonance imaging (MRI) and methods of making and purifying the same. More specifically, disclosed are such pharmaceutical formulations of chelate complexes with lanthanide metal ions, such as gadolinium ions, as well as methods for obtaining and purifying the same. In particular, the pharmaceutical formulations are free or substantially free of water molecules coordinated with the lanthanide metal chelate complexes and provide pharmaceutical compositions that are more stable and release less lanthanide ion, specifically gadolinium ion, into the human body when injected as MRI contrast agents as compared to other typically used MRI contrast agents.

This invention discloses a method for synthesizing a terbium complex fluorescent probe and its application in the detection of metronidazole, belonging to the field of food safety technology. This invention utilizes 2,6-difluorobenzoic acid and 1,10-phenanthroline as ligands to synthesize a luminescent rare earth complex [Tb2(2,6-dfba)6(phen)2] with Tb(NO3)3·6H2O. The crystal structure shows that it is a binuclear terbium complex, which exhibits strong Tb2 fluorescence at 489, 545, 584, and 621 nm. 3+ The complex exhibits characteristic emission peaks and good time stability of its fluorescence intensity. It specifically and sensitively recognizes metronidazole, demonstrating rapid response (<1 min), a low limit of detection (43.7 nM), and a wide linear detection range (0–100 μM). It can be used for the quantitative detection of metronidazole in animal feed.

The present invention provides a novel method for preparing high-purity gadobutrol or hydrates thereof. The preparation method of the present invention can have an advantage of simplifying a process by forming a gadolinium complex in-situ without purification of a butrol intermediate and omitting a resin purification process unlike a conventional method for synthesizing gadobutrol. In addition, the preparation method of the present invention can be used to produce high-purity gadobutrol or hydrates thereof at a high yield only through the simple process as above, and thus can be useful in mass production.

The invention discloses a time-resolved microsphere and a preparation method thereof. The preparation method comprises the following steps: S1, preparing a europium complex; s2, preparing white carboxyl latex microspheres; and S3, preparing the time-resolved microspheres by a swelling method. The time-resolved fluorescent microspheres prepared by the invention have the characteristics of high brightness, ultra-long fluorescence lifetime, excellent stability, good biocompatibility, easiness in functionalization and the like, so that the potential of a time-resolved fluorescence immunoassay technology is fully exerted, and the ever-increasing requirements of high sensitivity, high accuracy and rapid detection are met.

The application discloses a rare earth organic complex and a preparation method and application thereof, and has the structure shown in formula (I). The anti-radiation performance of the rare earth organic complex is improved, the rare earth organic complex has good absorption in an ultraviolet light region and a blue light region less than 500 nm, can be excited by light in a wavelength range less than 460 nm, is converted into visible light greater than 500 nm, and can be used for preparing a light conversion film.

Disclosed herein are compounds that target carbonic anhydrase 9 (CA IX) (such as compounds of structural formula (I) or (II) wherein values for variables are as described herein) and methods for the prevention and / or treatment of certain cancers, including solid tumors, using such compounds. Also disclosed herein are pharmaceutically acceptable salts of such compounds and pharmaceutical compositions comprising such compounds or salts for use in such methods of preventing or treating cancers.

The present invention relates to fibroblast activation protein (FAP) - based ligands assembled through tetrazine ligation and their use in radiotherapy and imaging. The FAP inhibitor (FAPi) ligand compounds provided herein comprises a FAP targeting moiety, a linker, an IsoF-TCO and a radiolabeled tetrazine. The FAPi targeting compounds are possessing advantageous pharmacokinetic properties and enable quick and efficient modifications of the radiopharmaceuticals allowing a fast renal excretion and reduced liver accumulation.

The invention discloses a near-infrared luminous rare earth complex and a preparation method thereof. The structural general formula of the rare earth complex is SmLnX2, and L represents crown ether ligands including 15-crown-5, 12-crown-4, 18-crown-6 introduced with different substituents, derivative aza crown ethers and the like; n is a coordination number and is 1 or 2 according to the size of a crown ether ring; x is a counter anion or a coordination anion and comprises an iodide ion, a bromide ion, a chloride ion, tetrafluoroborate and the like. The emission spectrum of the Sm < 2 + > complex is located in a near-infrared region, and the Sm < 2 + > complex has high photoluminescence quantum yield and can be used as a photoluminescence material.

A method for synthesizing complex mixed linker structures is provided. [Solution] Embodiments of the present disclosure describe materials comprising a metal component, a first polytopic ligand, and a second polytopic ligand that associate to form a complex mixed linker structure having a merge net. Embodiments of the present disclosure further describe methods of synthesizing the complex mixed linker structure, including contacting a metal precursor, a first ligand precursor, and a second ligand precursor under reaction conditions sufficient to form the complex mixed linker structure having a merge net.

The present invention relates to new macrocyclic ligands substituted by at least one picolinic ester group, to radioactive complexes thereof and to their use in medical imaging and / or therapy, in particular in interventional radiology. The present invention also relates to new processes for the preparation of the ligands according to the invention, and also to intermediates in the preparation thereof.

The invention discloses an indium-based hybrid metal halide crystal and a preparation method and application thereof, and is characterized in that the chemical formula of the indium-based hybrid metal halide crystal is [(CH3) 4N] 2 [InCl5 (DMF)]; wherein the DMF is N, N '-dimethylformamide; the indium-based hybrid metal halide crystal has a zero-dimensional structure; a metal ion In < 3 + > of halide anions in the zero-dimensional structure is coordinated with five Cl <-> and one N from an organic solvent DMF to form an octahedral configuration; the indium-based hybrid metal halide crystal belongs to a monoclinic system, and the space group is C2 / c. The fluorescent material has the properties of a fluorescent material and an afterglow material, and has the properties of converting ultraviolet light into visible light, emitting green afterglow in 3 seconds and preventing counterfeiting.

The present invention relates to a compound capable of thin film deposition and, specifically, to a novel compound applicable to atomic layer deposition (ALD) or chemical vapor deposition (CVD) and exhibiting excellent reactivity, volatility, and thermal stability, a method for preparing the compound, a precursor compound comprising the compound, and a method for manufacturing a thin film using the precursor compound.

The application discloses a high-temperature-resistant organic fluorescent powder and a preparation method thereof. The organic fluorescent powder comprises a fluorescent seed formed by a poly-methyl methacrylate (PMMA) coated Sm 0.4 Yb 0.2 Er 0.4 (HTTA)3Phen fluorescent material, and a silica aerogel layer coated on the surface of the fluorescent seed. In the preparation, the organic fluorescent seed is prepared first, then the fluorescent seed is introduced in the preparation of the silica aerogel, and finally the high-temperature-resistant organic fluorescent powder with a core-shell structure is synthesized. The high-temperature-resistant light conversion powder can not only realize up-conversion and down-conversion, but also can improve the high-temperature resistance and optical performance of the light conversion powder, reduce light loss, improve mechanical performance, and adapt to the preparation mode of downstream products such as high-temperature extrusion.

The invention discloses a europium-based fluorescent probe synergistically coordinated with citric acid, fluorescent hydrogel and application of the europium-based fluorescent probe and the fluorescent hydrogel in tetracycline detection, and belongs to the technical field of tetracycline detection. The preparation method of the europium-based fluorescent probe with citric acid synergistic coordination comprises the following steps: mixing and dissolving 2, 5-dihydroxyterephthalic acid, citric acid and a europium-based compound to form a precursor solution, reacting at 40-45 DEG C, after the reaction is finished, naturally cooling, centrifuging, washing and drying to obtain the europium-based fluorescent probe with citric acid synergistic coordination. And the citric acid synergistic coordination europium-based fluorescent probe and agarose act to generate the citric acid synergistic coordination fluorescent hydrogel. The europium-based fluorescent probe synergistically coordinated with citric acid has excellent water dispersibility and chemical stability, shows excellent luminescence characteristics, and has excellent sensing performance; and effective distinguishing of tetracycline antibiotics is realized through a principal component analysis technology.

To provide specific isomers of Gd(PCTA-tris-glutamic acid) and its derivatives that possess improved physico-chemical properties in terms of relaxivity and kinetic inertness.SOLUTION: The present invention relates to the RRR / SSS pair of enantiomers of Gd(PCTA-tris-glutamic acid), single enantiomers of the pair, pharmaceutically acceptable salts thereof, their amide derivatives, and compositions comprising at least 50% of these compounds.SELECTED DRAWING: None

The present invention relates to electronically doped semiconductor materials and electronic components comprising cerium-ethylenediamine ketone-type and cerium-salen-type composites. The present invention also relates to the use of the cerium-ethylenediamine ketone-type and cerium-salen-type composites as electron acceptors, particularly as p-dopants and electron transport materials in organic electronic components. Furthermore, the present invention relates to novel cerium-ethylenediamine ketone-type and cerium-salen-type composites.

The present invention relates to an improved process for the preparation of macrocyclic chelant 2,2′,2″-(10-(2-hydroxypropyl)-1,4,7,10-tetraazacyclododecane-1,4,7-triyl)triacetic acid of formula (1). The present invention further relates to the process for the preparation of metal complexes of macrocyclic chelant 2,2′,2″-(10-(2-hydroxypropyl)-1,4,7,10-tetraazacyclododecane-1,4,7-triyl)triacetic acid of formula (1) with purity greater than 99.0% by HPLC. The present invention also relates to an improved process for the preparation of gadolinium complex of formula (1a) with macrocyclic chelant 2,2′,2″-(10-(2-hydroxypropyl)-1,4,7,10-tetraazacyclododecane-1,4,7-triyl)triacetic acid of formula (1). The present invention further relates to a novel process for the preparation of calcium complex of formula (1b) with macrocyclic chelant 2,2′,2″-(10-(2-hydroxypropyl)-1,4,7,10-tetraazacyclododecane-1,4,7-triyl)triacetic acid of formula (1).